DOI 10.16047/j.cnki.cn14-1300/r.2018.04.004 2018-05-08 11:56:58 http://kns.cnki.net/kcms/detail/14.1300.r.20180508.1156.008.html 254 Proceeding of Clinical Medicine Apr. 2018 Vol 27 No. 4 J. 2012 13 2 140-144. 4. J. 2015 46 3 172-176. 5. 178 J. 2015 14 7 548-551. 6 DINC A KIZILKAYA BEJI N YALCIN O. Effect of pelvic floor muscle exercises in the treatment of urinary in- continence during pregnancy and the postpartum period J. Int Urogynecol J Pelvic Floor Dysfunct 2009 10 1223-1231. 7. 1. J. J. 2015 51 8 810-2012 33 16 3397. 812. 8. 2. J. J. 2011 2008 24 8 593. 12 2 88-92. 2017-07 - 16 3. 1988 1671-8631 2018 04-0254 - 06 H7N9 H1N1 1 1 2 1. 363000 2. 363000 H7N9 H1N1 7 H7N9 H7N9 15 H1N1 H1N1 22 2 72. 73% 1 18. 18% P < 0. 05 H7N9 100% H1N1 26. 67% P < 0. 05 H7N9 71. 43% 85. 71% 57. 14% H1N1 13. 33% 13. 33% 0 P < 0. 05 H7N9 26. 86 ± 13. 06 d H1N1 7. 20 ± 6. 46 d t = 4. 79 P < 0. 05 H7N9 H1N1 H7N9 A H1N1 R511. 7 B Clinical analysis of severe avian influenza H7N9 and severe influenza A H1N1 YE Yuming 1 LIN Li 1 LIU Jiannan 2 1. Zhangzhou Affiliated Hospital of FuJian Medical University Zhangzhou 363000 China 2. The Third Hospital of Zhangzhou Zhangzhou 363000 China Abstract Objective To investigate the clinical characteristics of severe avian influenza H7N9 and severe influenza A H1N1 to guide the diagnosis and treatment. Methods Seven cases of severe avian influenza H7N9 group hereinafter referred to as severe H7N9 group and 15 cases of severe influenza A H1N1 group hereinafter referred to as severe H1N1group were collected and retrospectively analyzed their similarities and differences in the general situation basic disease clinical symptoms inspection results imaging examinations treatment and prognosis. Results Among 22 patients the mortality rate of patients with 2 or more than 2 basic diseases was 72. 73% 8 /11 and the mortality rate of patients with one or more than one basic disease was 18. 18% 2 /11 P < 0. 05. The rate of peripheral blood lymphocyte descent in severe H7N9
2018 4 27 4 255 group was 100% 7 /7 higher than that in severe H1N1 group 26. 67% 4 /15 P < 0. 05. The incident rate of consolidation of lung pleural effusion and pericardial effusion in the severe H7 N9 group respectively were7 1. 4 3 % 5 / 7 8 5. 7 1 % 6 /7 and57. 14% 4 /7 whichwashigherthanthatofsevereh1 N1 group13. 33 % 2 / 15 13. 33 % 2 / 15 0 0 / 15 P < 0. 05. The time of mechanical ventilation in the severe H7N9 group was 26. 86 ± 13. 06 days in average which was higher than that of the severe H1N1 group 7. 20 ± 6. 46 days in average t = 4. 79 P < 0. 05. Through the follow - up visit between these two groups the severe H7N9 group had more fibrous stripes in the lung images which absorbed more slowly. Conclusion Compared with severe influenza A H1N1 the severe avian influenza H7N9 is worse in the disease of condition and prognosis. Key words influenza virus A H1N1 subtype avian influenza acute respiratory distress syndrome 2009 3 H1N1 2 H7N9 2013 2 2. 1 22 10 1-2 9 6 4 4 H7N9 4 3 1 H7N9 H1N1 H1N1 11 H7N9 5 H1N1 6 2 H7N9 2 H1N1 0 18. 18% 2 11 H7N9 2 H1N1 9 1 8 H7N9 2 H1N1 6 72. 73% 1. 1 1 2 Fisher 2011 1 1-2017 12 31 P < 0. 05 2. 2 H7N9 7 H7N9 H1N1 15 H1N1 H7N9 1 H7N9 39. 06 ± 0. 99 4 3 57. 57 ± 21. 63 H1N1 38. 58 ± 1. 19 H1N1 10 5 60. 27 ± 17. 53 t = 0. 92 P > 0. 05 H7N9 1 % t = - 0. 31 P > 0. 05 22 H1N1 H7N9 H1N1 n = 7 n = 15 H1N1 H7N9 H1N1 7 100. 00 12 80. 00 7 100. 00 15 100. 00 H1N1 2010 7 100. 00 13 86. 67 H7N9 2 28. 57 4 26. 67 0 0 2 13. 33 H7N9 4 57. 14 9 60. 00 2017 1 1. 2 2. 3 C C H1N1 H7N9 1. 3 Fisher SPSS 22. 0 P < 0. 05 2 H7N9 2 t Fisher P < 0. 05
256 Proceeding of Clinical Medicine Apr. 2018 Vol 27 No. 4 2 H7N9 H1N1 % H7N9 n = 7 H1N1 n = 15 H7N9 n = 7 H1N1 n = 15 H7N9 n = 7 H1N1 n = 15 1 14. 29 6 40. 00 3 42. 86 8 53. 33 3 42. 86 1 0. 07 0 0 6 40. 00 6 85. 71 8 53. 33 1 14. 29 1 0. 07 0 0 0 0 0 0 11 73. 33 7 100. 00 4 26. 67 1 0 0 1 0. 07 6 85. 71 13 86. 67 1 14. 29 1 0. 07 7 100. 00 14 93. 33 0 0 1 0. 07 0 0 0 0 4 57. 14 5 33. 33 3 42. 86 10 66. 67 0 0 0 0 6 85. 71 7 46. 67 1 14. 29 8 53. 33 0 0 0 0 0 0 0 0 0 0 4 26. 67 7 100. 00 11 73. 33 C 7 100. 00 13 86. 67 0 0 2 13. 33 0 0 0 0 7 100. 00 12 80. 00 0 0 3 33. 33 0 0 0 0 0 0 0 0 0 0 4 26. 67 7 100. 00 11 73. 33 0 0 1 0. 07 7 100. 00 14 93. 33 0 0 0 0 1 Fisher P < 0. 05 78 1 1 13 1 4 2 60 1 195 H1N1 1 8 3 2 1 13 3 1 1 1 6 3 1 H7N9 H1N1 % H7N9 2. 4 4 57. 14 4 26. 67 0. 343 H7N9 CT 3 0 0 0 0 4 CT 5 71. 43 2 13. 33 0. 014 CT H1N1 4 57. 14 12 80. 00 0. 334 3 42. 86 4 26. 67 0. 630 CT 10 5 0 0 1 0. 07 1. 000 CT 3 42. 86 2 13. 33 0. 274 3 0 0 1 0. 07 1 1. 000 6 85. 71 2 20. 00 0. 007 1 14. 29 0 0 H7N9 1 14. 29 0 0 H1N1 Fisher 4 57. 14 0 0 0. 005 P < 0. 05 1 14. 29 2 13. 33 1. 000 1 3 H7N9 42. 86% 2 H1N1 2. 5 3 H7N9 1 H7N9 6. 86 ± 3. 44 d 5 1 8 1 14 150 mg 2 CT RT - PCR H7N9 1 10. 33 ± 1. 97 d 6 1 9 H1N1 6 1 H1N1 7. 53 ± 5. 59 d 20 CT 7 75 mg 2 8 150 54 1 16 mg 2 RT - PCR H1N1 n = 7 H1N1 n = 15 P 0 0 1 0. 07 1 1. 000 7 100. 00 14 93. 33 1. 000
2018 4 27 4 257 12. 43 ± 4. 31 d 7 3 2 2 C H7N9 26. 86 ± 13. 06 11 - d H1N1 7. 20 ± 6. 46 d 12 t = 4. 79 P < 0. 05 H7 N9 7 ARDS H7N9 54. 39 ± 31. 58 mg /d H1N1 9 ARDS 5 26. 96 ± 17. 94 mg /d t = 2. 20 P < 0. 05 H7N9 2 500 mg /d 1 d 2 H7N9 31. 14 ± 14. 11 d H1N1 18. 4 ± 10. 37 d t = 2. 40 P < 0. 05 H7N9 4 57. 14% H1N1 6 40. 00% Fisher 11 P > 0. 05 3 CT H7N9 H1N1 13 HA NA 16 H H1 ~ H16 9 N N1 ~ N9 H7N9 H5 H7 H9 H10 14 H7N9 2009 H1N1 2013 H7N9 MCP - 1 IP - 10 H1N1 2 - IFN - γ IL - 6 MIG IL - 8 4 2 H7N9 H7N9 2 H7N9 H1N1 2 H7N9 2 H7N9 H1N1 H7N9 H7N9 3 H1N1 7 2 5 X H7N9 2 H7N9 H7N9 H1N1 5 H1N1 6-7 H1N1 15 2 H1N1 CT 8-10 H7N9
258 Proceeding of Clinical Medicine Apr. 2018 Vol 27 No. 4 1 2 Chen 16 H7N9 56 H7N9 CT 6 H1N1 6 1a 2 1b 10 CT 1c 40 CT 1d 60 1 1 H7N9 CT 2a 2b 5 CT 2c 2d 58 2 1 H1N1 CT 1 CHEN Y LIANG W YANG S et al. Human infections with the emerging avian influenza A H7N9 virus from 7. 76 H1N1 J. 2010 25 9 956-960. wet market poultry clinical analysis and characterisation of viral genome J. Lancet 2013 381 9881 1916-1925. 8 DAWOOD F S JAIN S FINELLI L et al. Emergence of a novel swine - origin influenza A H1N1 virus in humans J. N Engl J Med 2009 360 25 2605-2615. 2. 9. H7N9 D. 2015. D. 2014. 3 JIANG Y XU J ZHOU C et al. Characterization of cytokine / chemokine profiles of severe acute respiratory syndrome J. Am J Respir Crit Care Med 2005 171 8 850-857. 4 TANG N L CHAN P K WONG C K et al. Early en- 10 CHENG Q L DING H SUN Z et al. Retrospective study of risk factors for mortality in human avian influenza A H7N9 cases in Zhejiang Province China March 2013 to June 2014 J. Int J Infect Dis 2015 39 95-101. hanced expression of interferon - inducible protein - 10 CXCL - 10 and other chemokines predicts adverse 11. 480 H1N1 D. 2012. outcome in severe acute respiratory syndrome J. Clin Chem 2005 51 12 2333-2340. 12 SHEN Z CHEN Z LI X et al. Host immunological response and factors associated with clinical outcome in 5. H7N9 H5N1 ph1n1 D. 2013. patients with the novel influenza A H7N9 infection J. Clin Microbiol Infect 2014 20 8 493-500. 6. H7N9 H5N1 H10N8 J. 13 JOOB B WIWANITKIT V. Chest X - ray and CT findings 2015 27 5 549-553. in H7N9 influenza. Acta Radiol J. 2015 56 1 NP5.
2018 4 27 4 14 WANG Q ZHANG Z SHI Y et al. Emerging H7N9 influenza A novel reassortant avian - origin pneumonia radiologic findings J. Radiology 2013 268 3 882-889. 15 HUI D S LEE N CHAN P K. Adjunctive therapies and immunomodulatory agents in the management of severe 259 influenza J. Antiviral Res 2013 98 3 410-416. 16 CHEN J WU J HAO S et al. Long term outcomes in survivors of epidemic Influenza A H7N9 virus infection J. Sci Rep 2017 7 1 17275. 2018-01 - 26 1982 1671-8631 2018 04-0259 - 03 3 410005 3 AQP3 mrna 18 18 TEWL RT - PCR AQP3 mrna P < 0. 05 P < 0. 05 AQP3 mrna 0. 154 ± 0. 091 0. 401 ± 0. 121 P < 0. 05 AQP3 3 R556 B Expression of AQP3 in psoriatic lesions and its significance TANG Hua FENG Hao LIAO Yangying LI Lan XIAO Weirong Hunan Provincial People's Hospital Changsha 410005 China Abstract Objective To observe the expression of AQP3mRNA in psoriasis vulgaris and to discuss its function. Methods All 18 cases of unexposed skin lesions of psoriasis vulgaris and 18 cases of normal unexposed skin were collected. The value of sebum content trans - epidermal water loss TEWL and water content of stratum corneum were detected and the expression of AQP3 mrna of every case was detected by using RT - PCR. Results The water content and sebum content in the stratum corneum of psoriasis vulgaris were lower than those in the normal control group P < 0. 05 and the TEWL was higher than that in the normal control group P < 0. 05. The expression of AQP3mRNA in psoriasis vulgaris is 0. 154 ± 0. 091 and the expression of normal control group is 0. 401 ± 0. 121. AQP3mRNA in psoriasis vulgaris was markedly lower than the normal control group P < 0. 05. Conclusion The decrease of AQP3 expression may be one of the causes of dry lesion and skin barrier damage in psoriasis. Key words AQP3 psoriasis vulgaris skin barrier 3 - AQP3 4 AQP3 mrna 1 1 1. 1 2017 1 2017 6 18 3 AQP3 5 AQP3 4 2